Search for a report

Reports

  • You are here:
  • Home
  • Downloads
  • GLOBAL COMPANION DIAGNOSTICS MARKET FORECAST 2022-2030

GLOBAL COMPANION DIAGNOSTICS MARKET FORECAST 2022-2030

In terms of revenue, the global companion diagnostics market was valued at $4883.29 million in 2021 and is estimated to reach $15441.90 million by 2030, growing at a CAGR of 13.29% during the forecast period of 2022 to 2030.

GLOBAL COMPANION DIAGNOSTICS MARKET FORECAST 2022-2030

Global Companion Diagnostics Market by Technology (in Situ Hybridization, Polymerase Chain Reaction, Immunohistochemistry, Next Generation Sequencing, Other Technologies) Market by Indication (Oncology, Neurology, Infectious Diseases, Other Indications) Market by End-user (Pharmaceutical and Biopharmaceutical Companies, Reference Laboratories, Other End-users) Market by Products & Services (Assay Kits and Reagents, Software & Services) by Geography

Request free sample

In terms of revenue, the global companion diagnostics market was valued at $4883.29 million in 2021 and is estimated to reach $15441.90 million by 2030, growing at a CAGR of 13.29% during the forecast period of 2022 to 2030. The market study has also analyzed the impact of COVID-19 on the companion diagnostics market qualitatively as well as quantitatively.

To know more about this report, request a free sample copy

The number of commercialized predictive biomarker assays has significantly expanded, particularly for chronic diseases, to aid in the development of targeted treatments. In this regard, companion diagnostics entail a type of biomarker-based test or assay produced concurrently with the targeted drug development process using a methodology known as drug-diagnostic co-development.
Additionally, companion diagnostics offer crucial data for patient classification, enabling the efficient and secure use of related pharmaceutical or biological treatments. Companion diagnostics also assist medical personnel in evaluating the advantages and risks of therapeutic treatments for a patient.

Companion Diagnostics Market

Read our latest blog on the Companion Diagnostics Market

Key growth enablers of the global companion diagnostics market:

  • Growing popularity of precision medicines
  • Increasing number of cancer cases and mortalities
    • The World Health Organization (WHO) reports that after cardiovascular illnesses, cancer is the second-leading cause of mortality worldwide, accounting for approximately one in six fatalities.
    • Moreover, an estimated 10 million people died because of cancer-related causes in 2020.
    • Companion diagnostics are widely used in the detection of various types of cancers, such as lung cancer, breast cancer, colorectal cancer, blood cancer, and other types.
    • As a result, the rising incidence of cancer cases has boosted the development of medicine as well as treatment strategies over time.
  • Rising number of adverse drug reaction cases

Key growth restraining factors:

  • Country-specific reimbursement issues
    • Reimbursement is a critical factor for patients who access personalized medicine. Moreover, clinical cost-effectiveness is primarily considered in reimbursement decisions in countries such as Japan and the United States.
    • While Japan generally covers approved companion diagnostics under the National Health Insurance, the FDA approval does not assure coverage for companion diagnostics in the United States.
    • Furthermore, reimbursement of the majority of FDA-approved companion diagnostics is based on the costs related to the steps involved in carrying out the test and not the value of the product.
    • Thus, higher costs and unfavorable reimbursement issues restrict the growth of the global companion diagnostics market.
  • Frequent cases of leakage in companion diagnostics for oncology

Global Companion Diagnostics Market | Top Trends

  • In addition to oncology, where it has become the standard of treatment, precision medicine is being increasingly employed in other therapeutic disciplines, such as inflammatory, respiratory, infectious, and central nervous system issues. Moreover, this growth has been closely associated with the development of scientific knowledge about these diseases.
  • Deal-making, clinical practice, and the R&D pipeline have been significantly impacted by the expansion of companion diagnostics outside of oncology.
  • Despite a general reduction in the number of diagnostics deals, it has been found that companion diagnostics deals, as a share of all diagnostics partnerships, have remained largely consistent since 2018.

Market Segmentation – Technology, Indication, Products & Services, and End-User –

Market by Technology:

  • In Situ Hybridization
  • Polymerase Chain Reaction
  • Immunohistochemistry
  • Next Generation Sequencing
  • Other Technologies

Market by Indication:

  • Oncology
    • Oncology is set to be the fastest-growing and dominating indication during the forecast period.
    • Growing cancer cases worldwide is expected to boost the deployment of companion diagnostics devices in the field of oncology.
    • These companion diagnostic devices are heavily used in the oncology segment for the development of highly accurate medicine or therapy for particular cancer cases.
    • Further, according to company sources, Cancer Genetics Inc (United States) and LabCorp (United States) collaborated with Thermo Fisher Scientific (United States) in Thermo Fisher Scientific’s next-generation sequencing (NGS) companion diagnostics center of excellence program to boost research on cancer diagnostics.
  • Neurology
  • Infectious Disease
  • Other Indications

Market by End-User:

  • Pharmaceutical and Biopharmaceutical Companies
    • The pharmaceutical and biopharmaceutical companies segment, under the end-user category, is expected to grow with the highest CAGR during the forecast period. Also, pharmaceutical and biopharmaceutical companies captured the greatest revenue share in 2021.
    • The segment deals with companion diagnostic devices and kits with applications in pharmaceutical and biopharmaceutical companies.
    • They use companion diagnostic devices and kits to select suitable candidates for clinical trials and monitor a drug’s efficacy. Besides, the segment is primarily driven by increasing pharmaceutical R&D spending globally.
    • According to the Association of the British Pharmaceutical Industry (ABPI), the global pharmaceutical R&D spending in 2021 was $133 billion. Most of these investments are used for the development of novel drugs, expected to supplement the market growth of companion diagnostics.
  • Reference Laboratories
  • Other End-Users 

Market by Products & Services:

  • Assay Kits & Reagents
  • Software & Services

Geographical Study Based on Four Major Regions:

  • North America: The United States and Canada
  • Europe: France, the United Kingdom, Germany, France, Italy, Spain, Poland, the Netherlands, and Rest of Europe
  • Asia-Pacific: China, Japan, India, South Korea, Singapore, Indonesia, Australia & New Zealand, and Rest of Asia-Pacific
    • Asia-Pacific is set to be the fastest-growing region during the projected period.
    • Precision medicine technology has grown significantly in the Asia-Pacific. Moreover, numerous programs have been launched in this region to support the research and development of precision medicine solutions for improved patient health, as well.
    • Regulatory agencies, the pharmaceutical industry, diagnostic businesses, and service providers are working together to develop an international platform in order to improve access to precision medicine technologies and address regulatory as well as financing challenges.
    • Due to rising healthcare awareness and a stable economy that makes healthcare services more accessible and affordable, the companion diagnostics market in the Asia-Pacific is anticipated to expand in the upcoming years.
  • Rest of World: Latin America, the Middle East & Africa

Major players in the global companion diagnostics market:

  • Abbott Laboratories
  • Arup Laboratories
  • Biomerieux
  • Danaher Corporation
  • Illumina

Key strategies adopted by some of these companies:

Abbott declared that it would purchase Walk Vascular LLC, a commercial-stage medical device company, in September 2021. The business sells a system for mechanical aspiration thrombectomy that contributes to the removal of peripheral blood clots.

ARUP Consult, a free online exam selection and interpretation tool has updated the program with new information. It provides recommendations for ovarian cancer biomarker preoperative testing and malaria testing techniques.

Report Synopsis:

Report Scope Details
Forecast Years 2022-2030
Base Year 2021
Historical Years 2018-2021
Forecast Units Revenue ($ Million)
Segments Analyzed Technology, Indication, Products & Services, and End-User
Geographies Analyzed North America, Europe, Asia-Pacific, and Rest of World
Companies Analyzed

Abbott Laboratories, Almac Group, Arup Laboratories, Biocartis, Biomerieux SA, Danaher Corporation, GE Healthcare, Genomic Health, Illumina Inc, Qiagen NV, Agilent, Roche Diagnostics, Sysmex Corporation, Thermo Fisher Scientific Inc

  1. RESEARCH SCOPE & METHODOLOGY
    • STUDY OBJECTIVES
    • SCOPE OF STUDY
    • METHODOLOGY
    • ASSUMPTIONS & LIMITATIONS
  2. EXECUTIVE SUMMARY
    • MARKET SIZE & ESTIMATES
    • MARKET OVERVIEW
  3. MARKET DYNAMICS
    • KEY DRIVERS
      • GROWING NUMBER OF CANCER CASES AND MORTALITIES
      • INCREASING POPULARITY OF PRECISION MEDICINES
      • RISING NUMBER OF ADVERSE DRUG REACTION CASES
    • KEY RESTRAINTS
      • COUNTRY-SPECIFIC REIMBURSEMENT ISSUES
      • FREQUENT CASES OF LEAKAGE IN COMPANION DIAGNOSTICS FOR ONCOLOGY
  1. KEY ANALYTICS
    • IMPACT OF COVID-19 ON COMPANION DIAGNOSTICS MARKET
    • KEY MARKET TRENDS
    • PORTER’S FIVE FORCES ANALYSIS
      • BUYERS POWER
      • SUPPLIERS POWER
      • SUBSTITUTION
      • NEW ENTRANTS
      • INDUSTRY RIVALRY
    • OPPORTUNITY MATRIX
    • VENDOR LANDSCAPE
    • VALUE CHAIN ANALYSIS
    • KEY BUYING CRITERIA
    • REGULATORY FRAMEWORK
  2. MARKET BY TECHNOLOGY
    • IN SITU HYBRIDIZATION
    • POLYMERASE CHAIN REACTION
    • IMMUNOHISTOCHEMISTRY
    • NEXT GENERATION SEQUENCING
    • OTHER TECHNOLOGIES
  3. MARKET BY INDICATION
    • ONCOLOGY
    • NEUROLOGY
    • INFECTIOUS DISEASES
    • OTHER INDICATIONS
  4. MARKET BY END-USER
    • PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
    • REFERENCE LABORATORIES
    • OTHER END-USERS
  5. MARKET BY PRODUCTS & SERVICES
    • ASSAY KITS AND REAGENTS
    • SOFTWARE & SERVICES
  6. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED STATES
        • CANADA
    • EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED KINGDOM
        • GERMANY
        • FRANCE
        • SPAIN
        • ITALY
        • POLAND
        • NETHERLANDS
        • REST OF EUROPE
    • ASIA-PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • CHINA
        • JAPAN
        • INDIA
        • SOUTH KOREA
        • INDONESIA
        • SINGAPORE
        • AUSTRALIA & NEW ZEALAND
        • REST OF ASIA-PACIFIC
    • REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA
  1. COMPETITIVE LANDSCAPE
    • KEY STRATEGIC DEVELOPMENTS
      • MERGERS & ACQUISITIONS
      • PRODUCT LAUNCHES & DEVELOPMENTS
      • PARTNERSHIPS & AGREEMENTS
    • COMPANY PROFILES
      • ABBOTT LABORATORIES
      • AGILENT
      • ALAMC GROUP
      • ARUP LABORATORIES
      • BIOCARTIS
      • BIOMERIEUX SA
      • DANAHER CORPORATION
      • GE HEALTHCARE
      • GENOMIC HEALTH
      • ILLUMINA INC
      • MYRIAD GENETICS INC
      • QIAGEN NV
      • ROCHE DIAGNOSTICS
      • SYSMEX CORPORATION
      • THERMO FISHER SCIENTIFIC INC

LIST OF TABLES  

TABLE 1: MARKET SNAPSHOT – COMPANION DIAGNOSTICS

TABLE 2: NEW CASES OF CANCER PATIENTS IN 2020

TABLE 3: GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 4: GLOBAL COMPANION DIAGNOSTICS MARKET, BY TECHNOLOGY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 5: GLOBAL IN SITU HYBRIDIZATION MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 6: GLOBAL IN SITU HYBRIDIZATION MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 7: GLOBAL POLYMERASE CHAIN REACTION MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 8: GLOBAL POLYMERASE CHAIN REACTION MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 9: GLOBAL IMMUNOHISTOCHEMISTRY COMPANION DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 10: GLOBAL IMMUNOHISTOCHEMISTRY COMPANION DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 11: GLOBAL NEXT GENERATION SEQUENCING MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 12: GLOBAL NEXT GENERATION SEQUENCING MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 13: GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 14: GLOBAL OTHER TECHNOLOGIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 15: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 16: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INDICATION FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 17: GLOBAL ONCOLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 18: GLOBAL ONCOLOGY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 19: GLOBAL NEUROLOGY MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 20: GLOBAL NEUROLOGY MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 21: GLOBAL INFECTIOUS DISEASES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 22: GLOBAL INFECTIOUS DISEASES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 23: GLOBAL OTHER INDICATIONS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 24: GLOBAL OTHER INDICATIONS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 25: GLOBAL COMPANION DIAGNOSTICS MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 26: GLOBAL COMPANION DIAGNOSTICS MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 27: GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 28: GLOBAL PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 29: GLOBAL REFERENCE LABORATORIES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 30: GLOBAL REFERENCE LABORATORIES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 31: GLOBAL OTHER END-USERS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 32: GLOBAL OTHER END-USERS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 33: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 34: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 35: GLOBAL ASSAY KITS AND REAGENTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 36: GLOBAL ASSAY KITS AND REAGENTS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 37: GLOBAL SOFTWARE & SERVICES MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 38: GLOBAL SOFTWARE & SERVICES MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 39: GLOBAL COMPANION DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 40: GLOBAL COMPANION DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 41: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 42: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 43: LEADING PLAYERS OPERATING IN NORTH AMERICA COMPANION DIAGNOSTICS MARKET

TABLE 44: EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 45: EUROPE COMPANION DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 46: LEADING PLAYERS OPERATING IN EUROPE COMPANION DIAGNOSTICS MARKET

TABLE 47: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 48: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 49: LEADING PLAYERS OPERATING IN ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET

TABLE 50: REST OF WORLD COMPANION DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

TABLE 51: REST OF WORLD COMPANION DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

TABLE 52: LEADING PLAYERS OPERATING IN REST OF WORLD COMPANION DIAGNOSTICS MARKET

TABLE 53: LIST OF MERGERS & ACQUISITIONS

TABLE 54: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

TABLE 55: LIST OF PARTNERSHIPS & AGREEMENTS

LIST OF FIGURES 

FIGURE 1: CDX LEAKAGE

FIGURE 2: KEY MARKET TRENDS

FIGURE 3: PORTER’S FIVE FORCES ANALYSIS

FIGURE 4: OPPORTUNITY MATRIX

FIGURE 5: VENDOR LANDSCAPE

FIGURE 6: VALUE CHAIN ANALYSIS

FIGURE 7: FDA GUIDELINES FOR CDX APPROVAL

FIGURE 8: GLOBAL COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY TECHNOLOGY, IN 2021

FIGURE 9: GLOBAL COMPANION DIAGNOSTICS MARKET, BY IN SITU HYBRIDIZATION, 2022-2030 (IN $ MILLION)

FIGURE 10: GLOBAL COMPANION DIAGNOSTICS MARKET, BY POLYMERASE CHAIN REACTION, 2022-2030 (IN $ MILLION)

FIGURE 11: GLOBAL COMPANION DIAGNOSTICS MARKET, BY IMMUNOHISTOCHEMISTRY, 2022-2030 (IN $ MILLION)

FIGURE 12: GLOBAL COMPANION DIAGNOSTICS MARKET, BY NEXT GENERATION SEQUENCING, 2022-2030 (IN $ MILLION)

FIGURE 13: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER TECHNOLOGIES, 2022-2030 (IN $ MILLION)

FIGURE 14: GLOBAL COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY INDICATION, IN 2021

FIGURE 15: GLOBAL COMPANION DIAGNOSTICS MARKET, BY ONCOLOGY, 2022-2030 (IN $ MILLION)

FIGURE 16: GLOBAL COMPANION DIAGNOSTICS MARKET, BY NEUROLOGY, 2022-2030 (IN $ MILLION)

FIGURE 17: GLOBAL COMPANION DIAGNOSTICS MARKET, BY INFECTIOUS DISEASES, 2022-2030 (IN $ MILLION)

FIGURE 18: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER INDICATIONS, 2022-2030 (IN $ MILLION)

FIGURE 19: GLOBAL COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

FIGURE 20: GLOBAL COMPANION DIAGNOSTICS MARKET, BY PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES, 2022-2030 (IN $ MILLION)

FIGURE 21: GLOBAL COMPANION DIAGNOSTICS MARKET, BY REFERENCE LABORATORIES, 2022-2030 (IN $ MILLION)

FIGURE 22: GLOBAL COMPANION DIAGNOSTICS MARKET, BY OTHER END-USERS, 2022-2030 (IN $ MILLION)

FIGURE 23: GLOBAL COMPANION DIAGNOSTICS MARKET, GROWTH POTENTIAL, BY PRODUCTS & SERVICES, IN 2021

FIGURE 24: GLOBAL COMPANION DIAGNOSTICS MARKET, BY ASSAY KITS AND REAGENTS, 2022-2030 (IN $ MILLION)

FIGURE 25: GLOBAL COMPANION DIAGNOSTICS MARKET, BY SOFTWARE & SERVICES, 2022-2030 (IN $ MILLION)

FIGURE 26: NORTH AMERICA COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 27: UNITED STATES COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 28: CANADA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 29: EUROPE COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 30: UNITED KINGDOM COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 31: GERMANY COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 32: FRANCE COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 33: SPAIN COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 34: ITALY COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 35: POLAND COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 36: NETHERLANDS COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 37: REST OF EUROPE COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 38: ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

FIGURE 39: CHINA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 40: JAPAN COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 41: INDIA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 42: SOUTH KOREA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 43: INDONESIA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 44: THAILAND COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 45: AUSTRALIA & NEW ZEALAND COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 46: REST OF ASIA-PACIFIC COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 47: REST OF WORLD COMPANION DIAGNOSTICS MARKET, REGIONAL OUTLOOK, 2021 & 2030 (IN %)

FIGURE 48: LATIN AMERICA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

FIGURE 49: MIDDLE EAST & AFRICA COMPANION DIAGNOSTICS MARKET, 2022-2030 (IN $ MILLION)

  1. MARKET BY TECHNOLOGY
    • IN SITU HYBRIDIZATION
    • POLYMERASE CHAIN REACTION
    • IMMUNOHISTOCHEMISTRY
    • NEXT GENERATION SEQUENCING
    • OTHER TECHNOLOGIES
  2. MARKET BY INDICATION
    • ONCOLOGY
    • NEUROLOGY
    • INFECTIOUS DISEASES
    • OTHER INDICATIONS
  3. MARKET BY END-USER
    • PHARMACEUTICAL AND BIOPHARMACEUTICAL COMPANIES
    • REFERENCE LABORATORIES
    • OTHER END-USERS
  4. MARKET BY PRODUCTS & SERVICES
    • ASSAY KITS AND REAGENTS
    • SOFTWARE & SERVICES
  5. GEOGRAPHICAL ANALYSIS
    • NORTH AMERICA
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED STATES
        • CANADA
    • EUROPE
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • UNITED KINGDOM
        • GERMANY
        • FRANCE
        • SPAIN
        • ITALY
        • POLAND
        • NETHERLANDS
        • REST OF EUROPE
    • ASIA-PACIFIC
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • COUNTRY ANALYSIS
        • CHINA
        • JAPAN
        • INDIA
        • SOUTH KOREA
        • INDONESIA
        • SINGAPORE
        • AUSTRALIA & NEW ZEALAND
        • REST OF ASIA-PACIFIC
    • REST OF WORLD
      • MARKET SIZE & ESTIMATES
      • KEY GROWTH ENABLERS
      • KEY CHALLENGES
      • KEY PLAYERS
      • REGIONAL ANALYSIS
        • LATIN AMERICA
        • MIDDLE EAST & AFRICA

To request a free sample copy of this report, please complete the form below :

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    Frequently Asked Questions (FAQs):

    What is the worth of the Asia-Pacific companion diagnostics market?

    The Asia-Pacific companion diagnostics market size was valued at $1110.24 million in 2021.

    Which technology held the highest market share in 2021?

    The polymerase chain reaction segment, under the technology category, held the highest market share of around 37.80% in 2021.

    Which is the fastest-growing products & services in the market?

    Assay kits and reagents is the fastest-growing products & services in the market.

    To request a free sample copy of this report, please complete the form below:

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now